Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

HMS faculty, help us improve the algorithms in Profiles by uploading your CV!

Andrew Jay Wagner, M.D., Ph.D.


Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. Gounder MM, Agaram NP, Trabucco SE, Robinson V, Ferraro RA, Millis SZ, Krishnan A, Lee J, Attia S, Abida W, Drilon A, Chi P, Angelo SP, Dickson MA, Keohan ML, Kelly CM, Agulnik M, Chawla SP, Choy E, Chugh R, Meyer CF, Myer PA, Moore JL, Okimoto RA, Pollock RE, Ravi V, Singh AS, Somaiah N, Wagner AJ, Healey JH, Frampton GM, Venstrom JM, Ross JS, Ladanyi M, Singer S, Brennan MF, Schwartz GK, Lazar AJ, Thomas DM, Maki RG, Tap WD, Ali SM, Jin DX. Clinical genomic profiling in the management of patients with soft tissue and bone sarcoma. Nat Commun. 2022 06 15; 13(1):3406. PMID: 35705558; PMCID: PMC9200814.
    Citations:    Fields:    Translation:Humans
  2. Wagner AJ, Ravi V, Riedel RF, Ganjoo K, Van Tine BA, Chugh R, Cranmer L, Gordon EM, Hornick JL, Du H, Grigorian B, Schmid AN, Hou S, Harris K, Kwiatkowski DJ, Desai NP, Dickson MA. nab-Sirolimus for Patients With Malignant Perivascular Epithelioid Cell Tumors. J Clin Oncol. 2021 11 20; 39(33):3660-3670. PMID: 34637337; PMCID: PMC8601264.
    Citations: 4     Fields:    Translation:HumansCTClinical Trials
  3. Wagner AJ, Severson PL, Shields AF, Patnaik A, Chugh R, Tinoco G, Wu G, Nespi M, Lin J, Zhang Y, Ewing T, Habets G, Burton EA, Matusow B, Tsai J, Tsang G, Shellooe R, Carias H, Chan K, Rezaei H, Sanftner L, Marimuthu A, Spevak W, Ibrahim PN, Inokuchi K, Alcantar O, Michelson G, Tsiatis AC, Zhang C, Bollag G, Trent JC, Tap WD. Association of Combination of Conformation-Specific KIT Inhibitors With Clinical Benefit in Patients With Refractory Gastrointestinal Stromal Tumors: A Phase 1b/2a Nonrandomized Clinical Trial. JAMA Oncol. 2021 Sep 01; 7(9):1343-1350. PMID: 34236401; PMCID: PMC8267845.
    Citations: 3     Fields:    Translation:HumansCTClinical Trials
  4. Stacchiotti S, Frezza AM, Blay JY, Baldini EH, Bonvalot S, Bovée JVMG, Callegaro D, Casali PG, Chiang RC, Demetri GD, Demicco EG, Desai J, Eriksson M, Gelderblom H, George S, Gounder MM, Gronchi A, Gupta A, Haas RL, Hayes-Jardon A, Hohenberger P, Jones KB, Jones RL, Kasper B, Kawai A, Kirsch DG, Kleinerman ES, Le Cesne A, Lim J, Chirlaque López MD, Maestro R, Marcos-Gragera R, Martin Broto J, Matsuda T, Mir O, Patel SR, Raut CP, Razak ARA, Reed DR, Rutkowski P, Sanfilippo RG, Sbaraglia M, Schaefer IM, Strauss DC, Sundby Hall K, Tap WD, Thomas DM, van der Graaf WTA, van Houdt WJ, Visser O, von Mehren M, Wagner AJ, Wilky BA, Won YJ, Fletcher CDM, Dei Tos AP, Trama A. Ultra-rare sarcomas: A consensus paper from the Connective Tissue Oncology Society community of experts on the incidence threshold and the list of entities. Cancer. 2021 08 15; 127(16):2934-2942. PMID: 33910263; PMCID: PMC8319065.
    Citations: 6     Fields:    Translation:Humans
  5. Jones RL, Wagner AJ, Kawai A, Tamura K, Shahir A, Van Tine BA, Martín-Broto J, Peterson PM, Wright J, Tap WD. Prospective Evaluation of Doxorubicin Cardiotoxicity in Patients with Advanced Soft-tissue Sarcoma Treated in the ANNOUNCE Phase III Randomized Trial. Clin Cancer Res. 2021 07 15; 27(14):3861-3866. PMID: 33632930; PMCID: PMC8282740.
    Citations: 1     Fields:    Translation:HumansCTClinical Trials
  6. Gelderblom H, Wagner AJ, Tap WD, Palmerini E, Wainberg ZA, Desai J, Healey JH, van de Sande MAJ, Bernthal NM, Staals EL, Peterfy CG, Frezza AM, Hsu HH, Wang Q, Shuster DE, Stacchiotti S. Long-term outcomes of pexidartinib in tenosynovial giant cell tumors. Cancer. 2021 03 15; 127(6):884-893. PMID: 33197285; PMCID: PMC7946703.
    Citations: 5     Fields:    Translation:Humans
  7. Cote GM, Choy E, Chen T, Marino-Enriquez A, Morgan J, Merriam P, Thornton K, Wagner AJ, Nathenson MJ, Demetri G, George S. A phase II multi-strata study of lurbinectedin as a single agent or in combination with conventional chemotherapy in metastatic and/or unresectable sarcomas. Eur J Cancer. 2020 02; 126:21-32. PMID: 31896519.
    Citations: 5     Fields:    Translation:HumansCTClinical Trials
  8. Frezza AM, Assi T, Lo Vullo S, Ben-Ami E, Dufresne A, Yonemori K, Noguchi E, Siontis B, Ferraro R, Teterycz P, Duffaud F, Ravi V, Vincenzi B, Gelderblom H, Pantaleo MA, Baldi GG, Desar I, Fedenko A, Maki RG, Jones RL, Benjamin RS, Blay JY, Kawai A, Gounder M, Gronchi A, Le Cesne A, Mir O, Czarnecka AM, Schuetze S, Wagner AJ, Adam J, Barisella M, Sbaraglia M, Hornick JL, Meurgey A, Mariani L, Casali PG, Thornton K, Stacchiotti S. Systemic treatments in MDM2 positive intimal sarcoma: A multicentre experience with anthracycline, gemcitabine, and pazopanib within the World Sarcoma Network. Cancer. 2020 01 01; 126(1):98-104. PMID: 31536651; PMCID: PMC9187112.
    Citations: 8     Fields:    Translation:Humans
  9. Serrano C, Leal A, Kuang Y, Morgan JA, Barysauskas CM, Phallen J, Triplett O, Mariño-Enríquez A, Wagner AJ, Demetri GD, Velculescu VE, Paweletz CP, Fletcher JA, George S. Phase I Study of Rapid Alternation of Sunitinib and Regorafenib for the Treatment of Tyrosine Kinase Inhibitor Refractory Gastrointestinal Stromal Tumors. Clin Cancer Res. 2019 12 15; 25(24):7287-7293. PMID: 31471313.
    Citations: 14     Fields:    Translation:HumansCTClinical Trials
  10. Gluck WL, Gounder MM, Frank R, Eskens F, Blay JY, Cassier PA, Soria JC, Chawla S, de Weger V, Wagner AJ, Siegel D, De Vos F, Rasmussen E, Henary HA. Phase 1 study of the MDM2 inhibitor AMG 232 in patients with advanced P53 wild-type solid tumors or multiple myeloma. Invest New Drugs. 2020 06; 38(3):831-843. PMID: 31359240; PMCID: PMC7211202.
    Citations: 23     Fields:    Translation:HumansCTClinical Trials
  11. Amin-Mansour A, George S, Sioletic S, Carter SL, Rosenberg M, Taylor-Weiner A, Stewart C, Chevalier A, Seepo S, Tracy A, Getz G, Hornick JL, Nucci MR, Quade B, Demetri GD, Raut CP, Garraway LA, Van Allen EM, Wagner AJ. Genomic Evolutionary Patterns of Leiomyosarcoma and Liposarcoma. Clin Cancer Res. 2019 08 15; 25(16):5135-5142. PMID: 31164371.
    Citations: 7     Fields:    Translation:Humans
  12. Jones RL, Chawla SP, Attia S, Schöffski P, Gelderblom H, Chmielowski B, Le Cesne A, Van Tine BA, Trent JC, Patel S, Wagner AJ, Chugh R, Heyburn JW, Weil SC, Wang W, Viele K, Maki RG. A phase 1 and randomized controlled phase 2 trial of the safety and efficacy of the combination of gemcitabine and docetaxel with ontuxizumab (MORAb-004) in metastatic soft-tissue sarcomas. Cancer. 2019 07 15; 125(14):2445-2454. PMID: 31034598; PMCID: PMC6618088.
    Citations: 8     Fields:    Translation:HumansCTClinical Trials
  13. Doyle LA, Nowak JA, Nathenson MJ, Thornton K, Wagner AJ, Johnson JM, Albrayak A, George S, Sholl LM. Characteristics of mismatch repair deficiency in sarcomas. Mod Pathol. 2019 07; 32(7):977-987. PMID: 30765880.
    Citations: 13     Fields:    Translation:HumansCells
  14. Nakayama R, Jagannathan JP, Ramaiya N, Ferrone ML, Raut CP, Ready JE, Hornick JL, Wagner AJ. Clinical characteristics and treatment outcomes in six cases of malignant tenosynovial giant cell tumor: initial experience of molecularly targeted therapy. BMC Cancer. 2018 Dec 29; 18(1):1296. PMID: 30594158; PMCID: PMC6311045.
    Citations: 4     Fields:    Translation:Humans
  15. McCleary NJ, Healey MJ, Weng S, Song AB, Lederman RI, Ramelson HZ, Wagner AJ, Abel GA. Perceptions of Oncologists About Sharing Clinic Notes with Patients. Oncologist. 2019 01; 24(1):e46-e48. PMID: 30254186; PMCID: PMC6324628.
    Citations: 1     Fields:    Translation:Humans
  16. George S, Wagner AJ. Low Levels of Evidence for Neoadjuvant Chemotherapy to Treat Soft-Tissue Sarcoma. JAMA Oncol. 2018 09 01; 4(9):1169-1170. PMID: 29879275.
    Citations: 2     Fields:    Translation:Humans
  17. Kadish SS, Mayer EL, Jackman DM, Pomerantz M, Brady L, Dimitriadis A, Cleveland JLF, Wagner AJ. Implementation to Optimization: A Tailored, Data-Driven Approach to Improve Provider Efficiency and Confidence in Use of the Electronic Medical Record. J Oncol Pract. 2018 07; 14(7):e421-e428. PMID: 29939808.
    Citations: 6     Fields:    Translation:Humans
  18. McBride MJ, Pulice JL, Beird HC, Ingram DR, D'Avino AR, Shern JF, Charville GW, Hornick JL, Nakayama RT, Garcia-Rivera EM, Araujo DM, Wang WL, Tsai JW, Yeagley M, Wagner AJ, Futreal PA, Khan J, Lazar AJ, Kadoch C. The SS18-SSX Fusion Oncoprotein Hijacks BAF Complex Targeting and Function to Drive Synovial Sarcoma. Cancer Cell. 2018 06 11; 33(6):1128-1141.e7. PMID: 29861296; PMCID: PMC6791822.
    Citations: 65     Fields:    Translation:HumansCells
  19. Ben-Ami E, Barysauskas CM, Solomon S, Tahlil K, Malley R, Hohos M, Polson K, Loucks M, Severgnini M, Patel T, Cunningham A, Rodig SJ, Hodi FS, Morgan JA, Merriam P, Wagner AJ, Shapiro GI, George S. Immunotherapy with single agent nivolumab for advanced leiomyosarcoma of the uterus: Results of a phase 2 study. Cancer. 2017 Sep 01; 123(17):3285-3290. PMID: 28440953; PMCID: PMC5762200.
    Citations: 66     Fields:    Translation:HumansCTClinical Trials
  20. Hemming ML, Wagner AJ, Nucci MR, Chiang S, Wang L, Hensley ML, George S. YWHAE-rearranged high-grade endometrial stromal sarcoma: Two-center case series and response to chemotherapy. Gynecol Oncol. 2017 06; 145(3):531-535. PMID: 28390819; PMCID: PMC5471810.
    Citations: 8     Fields:    Translation:Humans
  21. de Jonge M, de Weger VA, Dickson MA, Langenberg M, Le Cesne A, Wagner AJ, Hsu K, Zheng W, Macé S, Tuffal G, Thomas K, Schellens JH. A phase I study of SAR405838, a novel human double minute 2 (HDM2) antagonist, in patients with solid tumours. Eur J Cancer. 2017 05; 76:144-151. PMID: 28324749.
    Citations: 39     Fields:    Translation:HumansCTClinical Trials
  22. Wagner AJ, Banerji U, Mahipal A, Somaiah N, Hirsch H, Fancourt C, Johnson-Levonas AO, Lam R, Meister AK, Russo G, Knox CD, Rose S, Hong DS. Phase I Trial of the Human Double Minute 2 Inhibitor MK-8242 in Patients With Advanced Solid Tumors. J Clin Oncol. 2017 Apr 20; 35(12):1304-1311. PMID: 28240971; PMCID: PMC5946729.
    Citations: 41     Fields:    Translation:HumansCTClinical Trials
  23. Jung J, Lee JS, Dickson MA, Schwartz GK, Le Cesne A, Varga A, Bahleda R, Wagner AJ, Choy E, de Jonge MJ, Light M, Rowley S, Macé S, Watters J. TP53 mutations emerge with HDM2 inhibitor SAR405838 treatment in de-differentiated liposarcoma. Nat Commun. 2016 08 31; 7:12609. PMID: 27576846.
    Citations: 32     Fields:    Translation:HumansCTClinical Trials
  24. Wagner AJ, Agulnik M, Heinrich MC, Mahadevan D, Riedel RF, von Mehren M, Trent J, Demetri GD, Corless CL, Yule M, Lyons JF, Oganesian A, Keer H. Dose-escalation study of a second-generation non-ansamycin HSP90 inhibitor, onalespib (AT13387), in combination with imatinib in patients with metastatic gastrointestinal stromal tumour. Eur J Cancer. 2016 07; 61:94-101. PMID: 27156227.
    Citations: 11     Fields:    Translation:HumansCTClinical Trials
  25. Nakayama R, Zhang YX, Czaplinski JT, Anatone AJ, Sicinska ET, Fletcher JA, Demetri GD, Wagner AJ. Preclinical activity of selinexor, an inhibitor of XPO1, in sarcoma. Oncotarget. 2016 Mar 29; 7(13):16581-92. PMID: 26918731.
    Citations: 32     Fields:    Translation:HumansAnimalsCells
  26. Dolly SO, Wagner AJ, Bendell JC, Kindler HL, Krug LM, Seiwert TY, Zauderer MG, Lolkema MP, Apt D, Yeh RF, Fredrickson JO, Spoerke JM, Koeppen H, Ware JA, Lauchle JO, Burris HA, de Bono JS. Phase I Study of Apitolisib (GDC-0980), Dual Phosphatidylinositol-3-Kinase and Mammalian Target of Rapamycin Kinase Inhibitor, in Patients with Advanced Solid Tumors. Clin Cancer Res. 2016 06 15; 22(12):2874-84. PMID: 26787751; PMCID: PMC4876928.
    Citations: 43     Fields:    Translation:HumansCTClinical Trials
  27. Yuan A, Kurtz SL, Barysauskas CM, Pilotte AP, Wagner AJ, Treister NS. Oral adverse events in cancer patients treated with VEGFR-directed multitargeted tyrosine kinase inhibitors. Oral Oncol. 2015 Nov; 51(11):1026-1033. PMID: 26403941.
    Citations: 10     Fields:    Translation:Humans
  28. Tap WD, Wainberg ZA, Anthony SP, Ibrahim PN, Zhang C, Healey JH, Chmielowski B, Staddon AP, Cohn AL, Shapiro GI, Keedy VL, Singh AS, Puzanov I, Kwak EL, Wagner AJ, Von Hoff DD, Weiss GJ, Ramanathan RK, Zhang J, Habets G, Zhang Y, Burton EA, Visor G, Sanftner L, Severson P, Nguyen H, Kim MJ, Marimuthu A, Tsang G, Shellooe R, Gee C, West BL, Hirth P, Nolop K, van de Rijn M, Hsu HH, Peterfy C, Lin PS, Tong-Starksen S, Bollag G. Structure-Guided Blockade of CSF1R Kinase in Tenosynovial Giant-Cell Tumor. N Engl J Med. 2015 Jul 30; 373(5):428-37. PMID: 26222558.
    Citations: 164     Fields:    Translation:HumansCTClinical Trials
  29. Tirumani SH, Wagner AJ, Tirumani H, Shinagare AB, Jagannathan JP, Hornick JL, George S, Ramaiya NH. Is the nonlipomatous component of dedifferentiated liposarcoma always soft tissue on CT? Analysis of CT densities and correlation with rate of growth in 60 patients. Abdom Imaging. 2015 Jun; 40(5):1248-54. PMID: 25287680.
    Citations: 2     Fields:    Translation:Humans
  30. Eilers G, Czaplinski JT, Mayeda M, Bahri N, Tao D, Zhu M, Hornick JL, Lindeman NI, Sicinska E, Wagner AJ, Fletcher JA, Mariño-Enriquez A. CDKN2A/p16 Loss Implicates CDK4 as a Therapeutic Target in Imatinib-Resistant Dermatofibrosarcoma Protuberans. Mol Cancer Ther. 2015 Jun; 14(6):1346-53. PMID: 25852058; PMCID: PMC4458458.
    Citations: 22     Fields:    Translation:HumansAnimalsCells
  31. Goldberg JM, Fisher DE, Demetri GD, Neuberg D, Allsop SA, Fonseca C, Nakazaki Y, Nemer D, Raut CP, George S, Morgan JA, Wagner AJ, Freeman GJ, Ritz J, Lezcano C, Mihm M, Canning C, Hodi FS, Dranoff G. Biologic Activity of Autologous, Granulocyte-Macrophage Colony-Stimulating Factor Secreting Alveolar Soft-Part Sarcoma and Clear Cell Sarcoma Vaccines. Clin Cancer Res. 2015 Jul 15; 21(14):3178-86. PMID: 25805798; PMCID: PMC4506240.
    Citations: 13     Fields:    Translation:HumansCTClinical Trials
  32. Choy E, Flamand Y, Balasubramanian S, Butrynski JE, Harmon DC, George S, Cote GM, Wagner AJ, Morgan JA, Sirisawad M, Mani C, Hornicek FJ, Duan Z, Demetri GD. Phase 1 study of oral abexinostat, a histone deacetylase inhibitor, in combination with doxorubicin in patients with metastatic sarcoma. Cancer. 2015 Apr 15; 121(8):1223-30. PMID: 25536954; PMCID: PMC4393337.
    Citations: 21     Fields:    Translation:HumansCTClinical Trials
  33. Wagner AJ, Messersmith WA, Shaik MN, Li S, Zheng X, McLachlan KR, Cesari R, Courtney R, Levin WJ, El-Khoueiry AB. A phase I study of PF-04449913, an oral hedgehog inhibitor, in patients with advanced solid tumors. Clin Cancer Res. 2015 03 01; 21(5):1044-51. PMID: 25388167.
    Citations: 30     Fields:    Translation:HumansCTClinical Trials
  34. Choy E, Butrynski JE, Harmon DC, Morgan JA, George S, Wagner AJ, D'Adamo D, Cote GM, Flamand Y, Benes CH, Haber DA, Baselga JM, Demetri GD. Phase II study of olaparib in patients with refractory Ewing sarcoma following failure of standard chemotherapy. BMC Cancer. 2014 Nov 05; 14:813. PMID: 25374341; PMCID: PMC4230717.
    Citations: 63     Fields:    Translation:HumansCTClinical Trials
  35. Sioletic S, Czaplinski J, Hu L, Fletcher JA, Fletcher CD, Wagner AJ, Loda M, Demetri GD, Sicinska ET, Snyder EL. c-Jun promotes cell migration and drives expression of the motility factor ENPP2 in soft tissue sarcomas. J Pathol. 2014 Oct; 234(2):190-202. PMID: 24852265; PMCID: PMC4472460.
    Citations: 15     Fields:    Translation:HumansAnimals
  36. Zhang YX, Sicinska E, Czaplinski JT, Remillard SP, Moss S, Wang Y, Brain C, Loo A, Snyder EL, Demetri GD, Kim S, Kung AL, Wagner AJ. Antiproliferative effects of CDK4/6 inhibition in CDK4-amplified human liposarcoma in vitro and in vivo. Mol Cancer Ther. 2014 Sep; 13(9):2184-93. PMID: 25028469.
    Citations: 52     Fields:    Translation:HumansAnimalsCells
  37. Wagner AJ. Patient-derived sarcoma xenografts for individual-patient selection of chemotherapy--ready for prime time? Cancer. 2014 Jul 01; 120(13):1917-9. PMID: 24706515.
    Citations: 2     Fields:    Translation:HumansAnimals
  38. Tirumani SH, Shinagare AB, Hargreaves J, Jagannathan JP, Hornick JL, Wagner AJ, Ramaiya NH. Imaging features of primary and metastatic malignant perivascular epithelioid cell tumors. AJR Am J Roentgenol. 2014 Feb; 202(2):252-8. PMID: 24450662.
    Citations: 29     Fields:    Translation:Humans
  39. George S, Feng Y, Manola J, Nucci MR, Butrynski JE, Morgan JA, Ramaiya N, Quek R, Penson RT, Wagner AJ, Harmon D, Demetri GD, Krasner C. Phase 2 trial of aromatase inhibition with letrozole in patients with uterine leiomyosarcomas expressing estrogen and/or progesterone receptors. Cancer. 2014 Mar 01; 120(5):738-43. PMID: 24222211.
    Citations: 32     Fields:    Translation:HumansCTClinical Trials
  40. Mason EF, Sadow PM, Wagner AJ, Remillard SP, Flood TA, Belanger EC, Hornick JL, Barletta JA. Identification of succinate dehydrogenase-deficient bladder paragangliomas. Am J Surg Pathol. 2013 Oct; 37(10):1612-8. PMID: 23797725.
    Citations: 7     Fields:    Translation:Humans
  41. Wagner AJ, Chugh R, Rosen LS, Morgan JA, George S, Gordon M, Dunbar J, Normant E, Grayzel D, Demetri GD. A phase I study of the HSP90 inhibitor retaspimycin hydrochloride (IPI-504) in patients with gastrointestinal stromal tumors or soft-tissue sarcomas. Clin Cancer Res. 2013 Nov 01; 19(21):6020-9. PMID: 24045182.
    Citations: 28     Fields:    Translation:HumansCTClinical Trials
  42. Wagner AJ. Sarcoma. Hematol Oncol Clin North Am. 2013 Oct; 27(5):xi-xii. PMID: 24093177.
    Citations:    Fields:    Translation:Humans
  43. Zhang YX, van Oosterwijk JG, Sicinska E, Moss S, Remillard SP, van Wezel T, Bühnemann C, Hassan AB, Demetri GD, Bovée JV, Wagner AJ. Functional profiling of receptor tyrosine kinases and downstream signaling in human chondrosarcomas identifies pathways for rational targeted therapy. Clin Cancer Res. 2013 Jul 15; 19(14):3796-807. PMID: 23714727.
    Citations: 31     Fields:    Translation:HumansAnimalsCells
  44. Wagner AJ, Remillard SP, Zhang YX, Doyle LA, George S, Hornick JL. Loss of expression of SDHA predicts SDHA mutations in gastrointestinal stromal tumors. Mod Pathol. 2013 Feb; 26(2):289-94. PMID: 22955521.
    Citations: 43     Fields:    Translation:Humans
  45. Tothova Z, Wagner AJ. Anaplastic lymphoma kinase-directed therapy in inflammatory myofibroblastic tumors. Curr Opin Oncol. 2012 Jul; 24(4):409-13. PMID: 22664824.
    Citations: 23     Fields:    Translation:Humans
  46. George S, Wang Q, Heinrich MC, Corless CL, Zhu M, Butrynski JE, Morgan JA, Wagner AJ, Choy E, Tap WD, Yap JT, Van den Abbeele AD, Manola JB, Solomon SM, Fletcher JA, von Mehren M, Demetri GD. Efficacy and safety of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of imatinib and sunitinib: a multicenter phase II trial. J Clin Oncol. 2012 Jul 01; 30(19):2401-7. PMID: 22614970.
    Citations: 97     Fields:    Translation:HumansCTClinical Trials
  47. Wagner AJ, Goldberg JM, Dubois SG, Choy E, Rosen L, Pappo A, Geller J, Judson I, Hogg D, Senzer N, Davis IJ, Chai F, Waghorne C, Schwartz B, Demetri GD. Tivantinib (ARQ 197), a selective inhibitor of MET, in patients with microphthalmia transcription factor-associated tumors: results of a multicenter phase 2 trial. Cancer. 2012 Dec 01; 118(23):5894-902. PMID: 22605650.
    Citations: 52     Fields:    Translation:HumansCTClinical Trials
  48. Pishvaian MJ, Marshall JL, Wagner AJ, Hwang JJ, Malik S, Cotarla I, Deeken JF, He AR, Daniel H, Halim AB, Zahir H, Copigneaux C, Liu K, Beckman RA, Demetri GD. A phase 1 study of efatutazone, an oral peroxisome proliferator-activated receptor gamma agonist, administered to patients with advanced malignancies. Cancer. 2012 Nov 01; 118(21):5403-13. PMID: 22570147; PMCID: PMC3726261.
    Citations: 29     Fields:    Translation:HumansCTClinical Trials
  49. Marrari A, Wagner AJ, Hornick JL. Predictors of response to targeted therapies for gastrointestinal stromal tumors. Arch Pathol Lab Med. 2012 May; 136(5):483-9. PMID: 22229850.
    Citations: 11     Fields:    Translation:Humans
  50. Riedel RF, Maki RG, Wagner AJ. Targeted therapy in sarcoma: should we be lumpers or splitters? Am Soc Clin Oncol Educ Book. 2012; 652-7. PMID: 24451813.
    Citations:    Fields:    
  51. Gutierrez A, Snyder EL, Marino-Enriquez A, Zhang YX, Sioletic S, Kozakewich E, Grebliunaite R, Ou WB, Sicinska E, Raut CP, Demetri GD, Perez-Atayde AR, Wagner AJ, Fletcher JA, Fletcher CD, Look AT. Aberrant AKT activation drives well-differentiated liposarcoma. Proc Natl Acad Sci U S A. 2011 Sep 27; 108(39):16386-91. PMID: 21930930; PMCID: PMC3182699.
    Citations: 26     Fields:    Translation:HumansAnimalsCells
  52. Cassier PA, Gelderblom H, Stacchiotti S, Thomas D, Maki RG, Kroep JR, van der Graaf WT, Italiano A, Seddon B, Dômont J, Bompas E, Wagner AJ, Blay JY. Efficacy of imatinib mesylate for the treatment of locally advanced and/or metastatic tenosynovial giant cell tumor/pigmented villonodular synovitis. Cancer. 2012 Mar 15; 118(6):1649-55. PMID: 21823110.
    Citations: 70     Fields:    Translation:Humans
  53. Rege TA, Wagner AJ, Corless CL, Heinrich MC, Hornick JL. "Pediatric-type" gastrointestinal stromal tumors in adults: distinctive histology predicts genotype and clinical behavior. Am J Surg Pathol. 2011 Apr; 35(4):495-504. PMID: 21358303.
    Citations: 23     Fields:    Translation:Humans
  54. Quek R, Wang Q, Morgan JA, Shapiro GI, Butrynski JE, Ramaiya N, Huftalen T, Jederlinic N, Manola J, Wagner AJ, Demetri GD, George S. Combination mTOR and IGF-1R inhibition: phase I trial of everolimus and figitumumab in patients with advanced sarcomas and other solid tumors. Clin Cancer Res. 2011 Feb 15; 17(4):871-9. PMID: 21177764.
    Citations: 85     Fields:    Translation:HumansCTClinical Trials
  55. Thomas DM, Wagner AJ. Specific targets in sarcoma and developmental therapeutics. J Natl Compr Canc Netw. 2010 Jun; 8(6):677-85; quiz 686. PMID: 20581299.
    Citations: 2     Fields:    Translation:Humans
  56. Davis IJ, McFadden AW, Zhang Y, Coxon A, Burgess TL, Wagner AJ, Fisher DE. Identification of the receptor tyrosine kinase c-Met and its ligand, hepatocyte growth factor, as therapeutic targets in clear cell sarcoma. Cancer Res. 2010 Jan 15; 70(2):639-45. PMID: 20068147.
    Citations: 41     Fields:    Translation:HumansAnimalsCells
  57. Wagner AJ, Malinowska-Kolodziej I, Morgan JA, Qin W, Fletcher CD, Vena N, Ligon AH, Antonescu CR, Ramaiya NH, Demetri GD, Kwiatkowski DJ, Maki RG. Clinical activity of mTOR inhibition with sirolimus in malignant perivascular epithelioid cell tumors: targeting the pathogenic activation of mTORC1 in tumors. J Clin Oncol. 2010 Feb 10; 28(5):835-40. PMID: 20048174; PMCID: PMC4810029.
    Citations: 126     Fields:    Translation:Humans
  58. Raut CP, Wang Q, Manola J, Morgan JA, George S, Wagner AJ, Butrynski JE, Fletcher CD, Demetri GD, Bertagnolli MM. Cytoreductive surgery in patients with metastatic gastrointestinal stromal tumor treated with sunitinib malate. Ann Surg Oncol. 2010 Feb; 17(2):407-15. PMID: 19898902.
    Citations: 28     Fields:    Translation:Humans
  59. George S, Merriam P, Maki RG, Van den Abbeele AD, Yap JT, Akhurst T, Harmon DC, Bhuchar G, O'Mara MM, D'Adamo DR, Morgan J, Schwartz GK, Wagner AJ, Butrynski JE, Demetri GD, Keohan ML. Multicenter phase II trial of sunitinib in the treatment of nongastrointestinal stromal tumor sarcomas. J Clin Oncol. 2009 Jul 01; 27(19):3154-60. PMID: 19451429.
    Citations: 112     Fields:    Translation:HumansCTClinical Trials
  60. Wagner AJ, Berliner N, Benz, EJ Jr. Anatomy and physiology of the gene, 5th Ed. In: Hoffman R, Benz EJ Jr, Shattil SJ, Furie B, Cohen HJ, Silberstein LE, McGlave P, editors. Hematology: Basic Principles and Practices. 2008; 2-16.
  61. Wagner AJ, Yazji S, Morgan JA, Choy E, Shen A, George S, Cancilla M, Kaiser P, Tap W, Hohos M, O'Mara M,Demetri GD. A phase 2 study of the KIT inhibitor XL820 in patients with advanced gastrointestinal stromal tumors (GIST) resistant to or intolerant of the tyrosine kinase inhibitors (TKI) imatinib and/or sunitinib. Connective Tissue Oncology Society Annual Meeting. 2008.
  62. LoRusso PM, Sarker D, Von Hoff D, Tibes R, Derynck MK, Ware JA, Yan Y, Demetri GD, de Bono JS, Wagner AJ. Pharmacokinetics and pharmacodynamic biomarkers for the pan-PI3K inhibitor GDC-0941: Initial Phase I evaluation. EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics. 2008.
  63. Mary Louise Keohan, Jeffrey Morgan, David R. D'Adamo, David Harmon, James Butrynski, Andrew J. Wagner, Timothy Akhurst, Gary K. Schwartz, Annick D. Van den Abbele, M. Travis Quigley, David Flanagan, Gauri Bhuchar, George D. Demetri, Robert G. Maki, and Suzanne George. A Phase II study of continuous dosing of sunitinib in patients with non-GIST soft tissue sarcomas: early results. Connective Tissue Oncologic Society Annual Meeting. 2007.
  64. Ito H, Hornick JL, Bertagnolli MM, George S, Morgan JA, Baldini EH, Wagner AJ, Demetri GD, Raut CP. Leiomyosarcoma of the inferior vena cava: survival after aggressive management. Ann Surg Oncol. 2007 Dec; 14(12):3534-41. PMID: 17896156.
    Citations: 29     Fields:    Translation:Humans
  65. Wagner A. Treatment of advanced soft tissue sarcoma: conventional agents and promising new drugs. J Natl Compr Canc Netw. 2007 Apr; 5(4):401-10. PMID: 17442231.
    Citations: 2     Fields:    Translation:Humans
  66. Stephen P. Remillard, Sarah Solomon, George D. Demetri, and Andrew J. Wagner. Predictors of TRAIL sensitivity and resistance in chondrosarcoma cell lines. Connective Tissue Oncologic Society Annual Meeting. 2007.
  67. C. P. Raut, J. A. Morgan, M. T. Quigley, S. George, A. J. Wagner, G. D. Demetri, M. M. Bertagnolli. Perioperative sunitinib dosing around extensive resections of imatinib-resistant metastatic gastrointestinal stromal tumors. American Society of Clinical Oncology Annual Meeting. 2007.
  68. Wagner AJ, Demetri GD. Pharmacology of Hematopoietic and Immune Cell Stimulation. In: Golan DE, Tashjian AH, Armstrong EJ, Armstrong AW, editors. Principles of Pharmacology: The Pathophysiologic Basis of Drug Therapy. 2007.
  69. G. D. Demetri, S. George, J. A. Morgan, A. Wagner, M. T. Quigley, K. Polson, J. Pokela, A. van den Abbeele, J. Adams, D. Grayzel. Inhibition of the Heat Shock Protein 90 (Hsp90) chaperone with the novel agent IPI-504 to overcome resistance to tyrosine kinase inhibitors (TKIs) in metastatic GIST: Updated results of a phase I trial. American Society of Clinical Oncology Annual Meeting. 2007.
  70. Wagner AJ. Treatment of Advanced Soft Tissue Sarcoma – Conventional Agents and Promising New Drugs. Journal of the National Comprehensive Cancer Network. 2007; 5:401-410.
  71. Wagner AJ, Fisher DE. Melanocyte signaling pathways and the etiology of melanoma. Drug Discovery Today: Disease Mechanisms. 2005; 2:179-183.
  72. Wagner AJ, Berliner N, Benz, EJ Jr. Anatomy and physiology of the gene, 4th Ed. In: Hoffman R, Benz EJ Jr, Shattil SJ, Furie B, Cohen HJ, Silberstein LE, McGlave P, editors. Hematology: Basic Principles and Practices. 2005; 2-16.
  73. Wagner AJ, Salgia R. Treatment of Relapsed and Refractory Small Cell Lung Cancer. Up to Date. 2002.
  74. Kokontis JM, Wagner AJ, O'Leary M, Liao S, Hay N. A transcriptional activation function of p53 is dispensable for and inhibitory of its apoptotic function. Oncogene. 2001 Feb 08; 20(6):659-68. PMID: 11313999.
    Citations: 17     Fields:    Translation:Humans
  75. Conzen SD, Gottlob K, Kandel ES, Khanduri P, Wagner AJ, O'Leary M, Hay N. Induction of cell cycle progression and acceleration of apoptosis are two separable functions of c-Myc: transrepression correlates with acceleration of apoptosis. Mol Cell Biol. 2000 Aug; 20(16):6008-18. PMID: 10913183.
    Citations: 34     Fields:    Translation:AnimalsCells
  76. Kennedy SG, Wagner AJ, Conzen SD, Jordán J, Bellacosa A, Tsichlis PN, Hay N. The PI 3-kinase/Akt signaling pathway delivers an anti-apoptotic signal. Genes Dev. 1997 Mar 15; 11(6):701-13. PMID: 9087425.
    Citations: 282     Fields:    Translation:AnimalsCells
  77. Eves EM, Boise LH, Thompson CB, Wagner AJ, Hay N, Rosner MR. Apoptosis induced by differentiation or serum deprivation in an immortalized central nervous system neuronal cell line. J Neurochem. 1996 Nov; 67(5):1908-20. PMID: 8863495.
    Citations: 14     Fields:    Translation:HumansAnimalsCells
  78. Uhlmann EJ, D'Sa-Eipper C, Subramanian T, Wagner AJ, Hay N, Chinnadurai G. Deletion of a nonconserved region of Bcl-2 confers a novel gain of function: suppression of apoptosis with concomitant cell proliferation. Cancer Res. 1996 Jun 01; 56(11):2506-9. PMID: 8653686.
    Citations: 11     Fields:    Translation:HumansCells
  79. Wagner AJ. Control of cellular proliferation and cell death by the product of the c-myc proto-oncogene. 1995.
  80. Wagner AJ, Kokontis JM, Hay N. Myc-mediated apoptosis requires wild-type p53 in a manner independent of cell cycle arrest and the ability of p53 to induce p21waf1/cip1. Genes Dev. 1994 Dec 01; 8(23):2817-30. PMID: 7995520.
    Citations: 134     Fields:    Translation:AnimalsCells
  81. Wagner AJ, Meyers C, Laimins LA, Hay N. c-Myc induces the expression and activity of ornithine decarboxylase. Cell Growth Differ. 1993 Nov; 4(11):879-83. PMID: 8297793.
    Citations: 45     Fields:    Translation:AnimalsCells
  82. Wagner AJ, Small MB, Hay N. Myc-mediated apoptosis is blocked by ectopic expression of Bcl-2. Mol Cell Biol. 1993 Apr; 13(4):2432-40. PMID: 8455620.
    Citations: 60     Fields:    Translation:AnimalsCells
  83. Amin C, Wagner AJ, Hay N. Sequence-specific transcriptional activation by Myc and repression by Max. Mol Cell Biol. 1993 Jan; 13(1):383-90. PMID: 8417337.
    Citations: 50     Fields:    Translation:Cells
  84. Wagner AJ, Le Beau MM, Diaz MO, Hay N. Expression, regulation, and chromosomal localization of the Max gene. Proc Natl Acad Sci U S A. 1992 Apr 01; 89(7):3111-5. PMID: 1557420; PMCID: PMC48814.
    Citations: 12     Fields:    Translation:HumansAnimalsCells
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact contactcatalyst.harvard.edu. For faculty or fellow appointment updates and changes, please ask your appointing department to contact HMS. For fellow personal and demographic information, contact HMS Human Resources at human_resourceshms.harvard.edu. For faculty personal and demographic information, contact HMS Office for Faculty Affairs at facappthms.harvard.edu.
Wagner's Networks
Click the
buttons for more information and interactive visualizations!
Concepts (357)
Co-Authors (63)
Similar People (60)
Same Department 
Physical Neighbors
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.